Synaptogenix, Inc.

Equities

SNPX

US87167T3005

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
4.53 ^USD	+2.65%		+4.62%	-33.36%

Apr. 09	Synaptogenix, Inc. acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd.	CI
Apr. 03	Synaptogenix Plans 1-for-25 Reverse Stock Split; Shares Fall	MT

Synaptogenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 14, 2023 at 05:01 pm EDT

Synaptogenix, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported net loss was USD 4.09 million compared to USD 3.75 million a year ago. Basic loss per share from continuing operations was USD 34.75 compared to USD 13.5 a year ago. Diluted loss per share from continuing operations was USD 34.75 compared to USD 13.5 a year ago.
For the six months, net loss was USD 5.81 million compared to USD 7.03 million a year ago. Basic loss per share from continuing operations was USD 41.5 compared to USD 25.25 a year ago. Diluted loss per share from continuing operations was USD 41.5 compared to USD 25.25 a year ago.

Latest news about Synaptogenix, Inc.

Synaptogenix, Inc. acquired Unknown Stake in Psyga Bio Ltd from Cannasoul Analytics Ltd.	Apr. 08	CI
Synaptogenix Plans 1-for-25 Reverse Stock Split; Shares Fall	Apr. 03	MT
Synaptogenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Synaptogenix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Synaptogenix, Inc. acquired 25% minority stake in Cannasoul Analytics Ltd. for $4 million.	Nov. 01	CI
Synaptogenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Synaptogenix, Inc. and Cleveland Clinic to Submit Investigational New Drug Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis	23-07-19	CI
Top Midday Gainers	23-07-13	MT
Synaptogenix, Inc.(NasdaqCM:SNPX) dropped from Russell Microcap Index	23-06-23	CI
Synaptogenix, Inc.(NasdaqCM:SNPX) dropped from Russell Microcap Growth Index	23-06-23	CI
Synaptogenix, Inc.(NasdaqCM:SNPX) dropped from Russell 3000E Growth Index	23-06-23	CI
Synaptogenix, Inc.(NasdaqCM:SNPX) dropped from Russell Microcap Value Index	23-06-23	CI
Synaptogenix, Inc.(NasdaqCM:SNPX) dropped from Russell 3000E Value Index	23-06-23	CI
Synaptogenix, Inc.(NasdaqCM:SNPX) dropped from Russell 3000E Index	23-06-23	CI
Synaptogenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
North American Morning Briefing : Futures Waver -2-	22-12-20	DJ
Maxim Downgrades Synaptogenix to Hold From Buy	22-12-19	MT
Sector Update: Health Care Stocks Stumble on Friday	22-12-16	MT
Sector Update: Healthcare	22-12-16	MT
Top Midday Decliners	22-12-16	MT
Synaptogenix Shares Decline After Proposed Alzheimer's Disease Treatment Misses Primary Endpoint in Phase 2 Study	22-12-16	MT
Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease	22-12-16	CI
Synaptogenix, Inc. announced that it has received $15 million in funding	22-11-20	CI
Synaptogenix Announces $15 Million Private Placement	22-11-18	MT
Synaptogenix, Inc. announced that it expects to receive $15 million in funding	22-11-16	CI

Chart Synaptogenix, Inc.

Duration

Period

More charts

Company Profile

Synaptogenix, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative disorders. The Company is principally focused on developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimerâs disease (AD), which is in the clinical testing stage. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. It has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in AD.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
SYNAPTOGENIX, INC.	-33.36%	4.92M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research